CDKN2A and gastric cancer: The mechanism suggested to be the basis of this differential CK4/6 inhibitor sensitivity of gastric cancer sub-types, p16 methylation, may serve as a biomarker to guide inclusion to a trial of CDK4/6 inhibitor as treatment in gastric cancers or other gastrointestinal trials.